S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
OTCMKTS:BIOVF

Swedish Orphan Biovitrum AB (publ) (BIOVF) Stock Price, News & Analysis

$26.95
0.00 (0.00%)
(As of 03/28/2024 ET)
Today's Range
$26.95
$26.95
50-Day Range
$23.32
$27.79
52-Week Range
$18.35
$27.79
Volume
N/A
Average Volume
85 shs
Market Capitalization
N/A
P/E Ratio
37.43
Dividend Yield
N/A
Price Target
N/A
BIOVF stock logo

About Swedish Orphan Biovitrum AB (publ) Stock (OTCMKTS:BIOVF)

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to treat paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Solna, Sweden.

BIOVF Stock Price History

BIOVF Stock News Headlines

Swedish Orphan Biovitrum AB (publ) (SWOBY)
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Invitation: Sobi's Q4 and FY 2023 report
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Swedish Orphan Biovitrum AB BIOVF
Sobi has completed the issuances of series C shares
Reminder: Invitation: Sobi's Q3 2023 report
Invitation: Sobi's Q3 2023 report
Sobi KOL investor event: the journey for Vonjo®
Invitation: Sobi's Q2 2023 report
See More Headlines
Receive BIOVF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Swedish Orphan Biovitrum AB (publ) and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/08/2024
Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
N/A
Sub-Industry
N/A
Current Symbol
OTCMKTS:BIOVF
CIK
N/A
Fax
N/A
Employees
1,612
Year Founded
2001

Profitability

Net Income
$227.17 million
Pretax Margin
13.35%

Debt

Sales & Book Value

Annual Sales
$2.09 billion
Cash Flow
$1.90 per share
Book Value
$10.82 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
0.48

Social Links

Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Guido Oelkers (Age 59)
    CEO & President
    Comp: $22.78M
  • Mr. Henrik Stenqvist (Age 57)
    Chief Financial Officer
  • Mr. Torbjörn Hallberg (Age 55)
    General Counsel & Head of Legal Affairs
  • Mr. Daniel Rankin (Age 44)
    Head of Strategy & Corporate Development
  • Ms. Lena Bjurner (Age 56)
    Head of Human Resources
  • Mr. Armin Reininger M.D. (Age 67)
    Ph.D., Senior Scientific & Medical Advisor
  • Mr. Norbert Oppitz (Age 57)
    Head of International
  • Mr. Sofiane Fahmy (Age 52)
    Head of Europe
  • Mr. Duane H. Barnes (Age 64)
    Head of North America
  • Mr. Mahmood Ladha (Age 60)
    Head of Strategic Transformation Operations

BIOVF Stock Analysis - Frequently Asked Questions

Should I buy or sell Swedish Orphan Biovitrum AB (publ) stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Swedish Orphan Biovitrum AB (publ) in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BIOVF shares.
View BIOVF analyst ratings
or view top-rated stocks.

How have BIOVF shares performed in 2024?

Swedish Orphan Biovitrum AB (publ)'s stock was trading at $26.25 at the start of the year. Since then, BIOVF stock has increased by 2.7% and is now trading at $26.9480.
View the best growth stocks for 2024 here
.

Are investors shorting Swedish Orphan Biovitrum AB (publ)?

Swedish Orphan Biovitrum AB (publ) saw a increase in short interest in February. As of February 29th, there was short interest totaling 644,500 shares, an increase of 18.7% from the February 14th total of 543,100 shares. Based on an average trading volume of 100 shares, the short-interest ratio is currently 6,445.0 days.
View Swedish Orphan Biovitrum AB (publ)'s Short Interest
.

How were Swedish Orphan Biovitrum AB (publ)'s earnings last quarter?

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) issued its earnings results on Thursday, February, 8th. The company reported $0.30 EPS for the quarter, missing analysts' consensus estimates of $0.56 by $0.26. The business earned $643.39 million during the quarter, compared to analyst estimates of $668.74 million. Swedish Orphan Biovitrum AB (publ) had a net margin of 10.95% and a trailing twelve-month return on equity of 8.93%.

How do I buy shares of Swedish Orphan Biovitrum AB (publ)?

Shares of BIOVF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:BIOVF) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners